How semaglutide tablets work for weight loss

What does semaglutide actually do inside the body?

GLP-1 (glucagon-like peptide-1) is a hormone released naturally from cells in your gut after eating. Its job is to tell the brain the meal has arrived: slow down digestion, reduce hunger, stop sending signals to eat more. Semaglutide is a synthetic version of that hormone, engineered to last far longer than the body's own GLP-1, which disappears within minutes.

When the tablet's semaglutide reaches the bloodstream, it binds to GLP-1 receptors in the brain, the pancreas and the stomach. Appetite signals quieten. Gastric emptying (how fast food moves from the stomach into the small intestine) slows down, which extends the feeling of fullness after a meal. The pancreas also responds more sensitively to blood sugar, which matters for people who have prediabetes or type 2 diabetes alongside their weight concerns.

The result, over weeks of treatment, is that many people find they are satisfied with smaller portions and feel less drawn to snacking between meals. That isn't willpower; it's receptor-level biology. The NHS semaglutide medicine page describes this mechanism in plain terms for patients wanting the official summary.

One thing our prescribers are asked most weeks: does the tablet work differently from the injection? Mechanistically, no, both activate the same GLP-1 receptor. The difference is in the journey the medicine takes to get there, and if you want a thorough answer to that question, our page on whether semaglutide tablets actually work walks through the science in detail.

How does an oral drug survive the stomach when injected drugs don't need to?

This is where the tablet's real innovation lies. Semaglutide is a peptide (a small protein) and the stomach's acid and digestive enzymes would ordinarily break it down before it could be absorbed, just as they digest a piece of chicken. That's why earlier GLP-1 medicines were injections: they bypass the digestive system entirely.

The Wegovy tablet solves this with a co-formulation agent called SNAC (sodium N-[8-(2-hydroxybenzoyl) aminocaprylate]). SNAC creates a localised, mildly alkaline environment right around the tablet as it dissolves in the stomach, which shields the semaglutide from acid breakdown. It also temporarily increases the permeability of the stomach lining in a small, localised area, allowing the semaglutide molecule to pass through the gastric mucosa directly into the bloodstream rather than waiting to be absorbed further down the gut.

This mechanism is why the taking instructions are unusually precise. The tablet must be swallowed first thing in the morning, on a completely empty stomach, with no more than around 120ml of plain water. Any food, other drink or additional medicines taken within 30 minutes reduce absorption significantly. The instructions aren't bureaucratic caution; they're how the medicine gets in at all. You can read the full detail in the Wegovy tablet SmPC on the eMC.

If you're exploring whether the oral tablet suits you better than the injection, the taking requirements are one of the most practical factors to weigh up.

What does the trial evidence say about how well it works?

The OASIS 4 phase-3 trial followed 307 adults with obesity or overweight plus at least one weight-related condition, without diabetes, over 64 weeks. All participants followed lifestyle guidance alongside treatment. Those taking the semaglutide tablet lost an average of around 13.6% of body weight compared with around 2.4% in the placebo group. Among participants who stayed fully adherent to treatment throughout the trial, average weight loss was around 16.6%.

That adherence finding matters. The tablet's absorption is more sensitive to how it's taken than an injection is, so people who followed the morning routine precisely got more from it. That's not a flaw in the medicine; it's a prompt to take the morning ritual seriously from day one.

The most common side effects reported were gastrointestinal (nausea, diarrhoea, constipation) occurring in around 74% of the semaglutide group versus 42% in the placebo group. Most were mild to moderate and settled as the dose was titrated slowly upward. This pattern mirrors what happens with the injection, and the gradual dose schedule (starting at just 1.5mg) exists specifically to give the body time to adapt. For more on the evidence, see our evidence page on whether semaglutide tablets work, and the MHRA's approval announcement from 11 June 2026 confirms these figures in the public record.

For context on what this looks like across a treatment journey, the Wegovy pill overview covers the full dosing schedule and what to expect at each stage.

Who can take semaglutide tablets, and what does the prescriber look for?

The Wegovy tablet is licensed for adults with a BMI of 30 or above, or 27–29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. It is not currently available on the NHS; a NICE appraisal would need to conclude first, so access is currently through private prescription only.

The prescription is the key point. Semaglutide tablets are a prescription-only medicine, and a clinician reviews your full health picture before one is issued, current medications, medical history, weight-related conditions, and whether the tablet or the injection is the more suitable form for you. People who are already established on the 2.4mg weekly injection may, subject to clinical assessment, move directly to the 25mg maintenance tablet rather than stepping through all four oral doses from the beginning.

The tablet is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. It is not licensed for under-18s. Certain conditions (including a history of pancreatitis or specific thyroid conditions) require careful prescriber discussion before treatment can be considered.

If you'd like to understand whether semaglutide pills are the right fit for your situation, or want to look at the cost of Wegovy tablets in the UK private market, both pages go into those specifics. Treatment options across the weight-loss medicines we prescribe are worth reviewing together before a consultation. When you're ready, a prescriber at our weight-loss treatment page can assess whether semaglutide tablets are clinically suitable for you, free, with no obligation.